Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases

Lü, Bin; Xiong, Su-Bin; Yang, Hong; Yin, Xiaodong; Ruo-bing, Chao

doi:10.1016/j.ejps.2006.01.001

Cited by 103 publications

(54 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Doxorubicin, an anticancer drug encapsulated into PLN, an advanced form of SLN, was found to be very effective in treating multidrug resistant breast cancer (121). Inspiring efficacy and tumor targeting have been reported to be enhanced with SLNs loaded with various anticancer drugs like doxorubicin (122) and mitoxantron (123).…”

Section: Chemotherapymentioning

confidence: 99%

Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: Pregled

Pardeshi¹,

Rajput²,

Belgamwar³

et al. 2012

Acta Pharmaceutica

178

View full text Add to dashboard Cite

In the era of nanoparticulate controlled and site specific drug delivery systems, use of solid lipids to produce first generation lipid nanoparticles, solid lipid nanoparticles (SLN), became a revolutionary approach in the early nineties. The present review is designed to provide an insight into how SLN are finding a niche as promising nanovectors and forms a sound basis to troubleshoot the existing problems associated with traditional systems. Herein, authors had tried to highlight the frontline aspects prominent to SLN. An updated list of lipids, advanced forms of SLN, methods of preparation, characterization parameters, and various routes of administration of SLN are explored in-depth. Stability, toxicity, stealthing, targeting efficiency and other prospectives of SLN are also discussed in detail. The present discussion embodies the potential of SLN, now being looked up by various research groups around the world for their utility in the core areas of pharmaceutical sciences, thereby urging pharmaceutical industries to foster their scale-up.

show abstract

Section: Chemotherapymentioning

confidence: 99%

Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: Pregled

Pardeshi¹,

Rajput²,

Belgamwar³

et al. 2012

Acta Pharmaceutica

178

View full text Add to dashboard Cite

show abstract

“…SLNs in breast cancer and lymph node metastases Mitoxantrone-loaded SLN local injections wereformulated to reduce the toxicity and improve thesafety and bioavailability of drug [21]. Efficacy ofdoxorubicin (Dox) has been reported to beenhanced by incorporation in SLNs.In themethodology the Dox was complexed withsoybean-oil-based anionic polymer anddispersed together with a lipid in water to formDox-loaded solid lipid nanoparticles.…”

Section: 5mentioning

confidence: 99%

Solid Lipid Nanoparticle: A Review

Joshi¹

2012

iosrphr

View full text Add to dashboard Cite

“…26 In addition, this targeting strategy typically leverages the overexpression of enzymes, decrease in pH, 26,31,32 leakiness of the tissue, and/or enhanced tissue retention of the nanosized particles. 23,29 These features can be exploited to activate the circulating NP drug carriers at the target organ or disease site. 33,34 The presence and integrity of the glycocalyx coating of the EC play a critical role in the cellular uptake of circulating NPs.…”

Section: Introductionmentioning

confidence: 99%

“…22,23 Lengthening NP residence times in the blood stream, through delaying clearance by the immune system or filtration by the kidneys, is achieved by covering the NPs with neutrally charged polymer coatings. [23][24][25][26][27] While local injection of NP-based materials is available for joint and wound therapy, 25,28,29 there are several common scenarios that require delivery to difficult-to-reach or unknown locations, such as tumors and metastatic disease. These situations often involve systemic administration through either oral ingestion or, relevant to the present study, venous injection.…”

Section: Introductionmentioning

confidence: 99%

Endothelial glycocalyx conditions influence nanoparticle uptake for passive targeting

Cheng¹,

Kumar²,

Sridhar³

et al. 2016

IJN

View full text Add to dashboard Cite

Cardiovascular diseases are facilitated by endothelial cell (EC) dysfunction and coincide with EC glycocalyx coat shedding. These diseases may be prevented by delivering medications to affected vascular regions using circulating nanoparticle (NP) drug carriers. The objective of the present study was to observe how the delivery of 10 nm polyethylene glycol-coated gold NPs (PEG-AuNP) to ECs is impacted by glycocalyx structure on the EC surface. Rat fat pad endothelial cells were chosen for their robust glycocalyx, verified by fluorescent immunolabeling of adsorbed albumin and integrated heparan sulfate (HS) chains. Confocal fluorescent imaging revealed a ~3 µm thick glycocalyx layer, covering 75% of the ECs and containing abundant HS. This healthy glycocalyx hindered the uptake of PEG-AuNP as expected because glycocalyx pores are typically 7 nm wide. Additional glycocalyx models tested included: a collapsed glycocalyx obtained by culturing cells in reduced protein media, a degraded glycocalyx obtained by applying heparinase III enzyme to specifically cleave HS, and a recovered glycocalyx obtained by supplementing exogenous HS into the media after enzyme degradation. The collapsed glycocalyx waŝ2 µm thick with unchanged EC coverage and sustained HS content. The degraded glycocalyx showed similar changes in EC thickness and coverage but its HS thickness was reduced to 0.7 µm and spanned only 10% of the original EC surface. Both dysfunctional models retained six- to sevenfold more PEG-AuNP compared to the healthy glycocalyx. The collapsed glycocalyx permitted NPs to cross the glycocalyx into intracellular spaces, whereas the degraded glycocalyx trapped the PEG-AuNP within the glycocalyx. The repaired glycocalyx model partially restored HS thickness to 1.2 µm and 44% coverage of the ECs, but it was able to reverse the NP uptake back to baseline levels. In summary, this study showed that the glycocalyx structure is critical for NP uptake by ECs and may serve as a passive pathway for delivering NPs to dysfunctional ECs.

show abstract

Solid lipid nanoparticles of mitoxantrone for local injection against breast cancer and its lymph node metastases

Cited by 103 publications

References 10 publications

Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: Pregled

Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: Pregled

Solid Lipid Nanoparticle: A Review

Endothelial glycocalyx conditions influence nanoparticle uptake for passive targeting

Contact Info

Product

Resources

About